Fingerprint
Dive into the research topics of 'Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
Jeffrey J. Raizer*, Mark G. Malkin, Martin Kleber, Lauren E. Abrey
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
26
Scopus
citations